What is Raynaud’s phenomenon? Raynaud’s phenomenon is a condition that affects your blood vessels. If you have Raynaud’s phenomenon, you have periods of time called “attacks” when your body does not send enough blood to the hands and feet. Attacks usually happen when you are cold or feeling stressed. During an attack, your fingers and toes may feel very cold or numb. Raynaud’s phenomenon is also called Raynaud’s disease or Raynaud’s syndrome.
¿Qué es el fenómeno de Raynaud? El fenómeno de Raynaud es una enfermedad que afecta los vasos sanguíneos. Si usted tiene el fenómeno de Raynaud, tiene periodos llamados "episodios" cuando el cuerpo no envía suficiente sangre a las manos y los pies. Los episodios generalmente ocurren cuando la persona tiene frío o se siente estresada. Durante un episodio, los dedos de las manos y los pies pueden sentirse muy fríos o entumecidos. El fenómeno de Raynaud también se conoce como la enfermedad de Raynaud o el síndrome de Raynaud.
Two new studies funded in part by NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) describe efforts to develop stem cell-based approaches for treating Epidermolysis Bullosa (EB), a rare, genetic skin disease. The findings, which were published jointly in the journal, Science Translational Medicine, may lead to individualized therapies for EB, and possibly other genetic diseases. People with EB have skin that is so fragile that the slightest friction causes blisters. The severity of the disease ranges from limited tearing of skin on the hands and feet to widespread blistering and scarring, including mucosal surfaces like the
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.